# www.publichealth.hscni.net

# Influenza Weekly Surveillance Bulletin

Northern Ireland, Week 12 (20 March 2017 - 26 March 2017)

# **Summary**

At this point in the 2016/17 influenza season, influenza continues to circulate at low levels across the region with decreases noted in a number of indicators in week 12 (week commencing 20<sup>th</sup> March 2017).

## Weekly Influenza GP Consultation Rates

- GP consultation rates for combined flu and flu-like illness (flu/FLI) have decreased in week 12, 2017 to 11.2 per 100,000 population. Rates remain below the 2016/17 pre-epidemic threshold<sup>1</sup>
- OOH GP consultation rates for flu/FLI decreased to 2.6 per 100,000 population in week 12, 2017

## Microbiological Surveillance

 The proportion of positive influenza detections from both sentinel and non-sentinel sources was 4% in week 12

# Respiratory Syncytial Virus (RSV) Activity

RSV activity has decreased from week 11 with levels lower than the same period last season

#### Influenza Confirmed Intensive Care Unit (ICU) Cases and Deaths

- One new case was reported in ICU with laboratory confirmed influenza in week 12, there have been a total of 40 cases this season
- No deaths were reported in week 12 among ICU patients with laboratory confirmed influenza; there have been a total of seven deaths in ICU patients with laboratory confirmed influenza this season

#### Influenza Outbreaks across Northern Ireland

 No confirmed influenza outbreaks were reported to the PHA. There have been a total of 11 confirmed influenza outbreaks this season

# Influenza Vaccine Uptake in Northern Ireland

 To 31<sup>st</sup> January 2017; uptake was 71.7% among those aged 65 years and over, 55.9% among those under 65 in an at risk group, 52.0% among 2-4 year olds and 78.2% among primary school children

<sup>&</sup>lt;sup>1</sup> The pre-epidemic threshold for Northern Ireland is 47.9 per 100,000 population this year (2016/17)

## Introduction

Influenza is an acute viral infection of the respiratory tract (nose, mouth, throat, bronchial tubes and lungs). There are three types of flu virus: A, B and C, with A and B responsible for most clinical illness. Influenza activity in Northern Ireland is monitored throughout the year to inform public health action and to prevent spread of the infection. The influenza season typically runs from week 40 to week 20. Week 40 for the 2016/17 season commenced on 3<sup>rd</sup> October 2016.

Surveillance systems used to monitor influenza activity include:

- GP sentinel surveillance representing 11.7% of Northern Ireland population;
- GP Out-of-Hours surveillance system representing the entire population;
- Virological reports from the Regional Virus Laboratory (RVL);
- Influenza outbreak report notification to PHA Duty Room;
- Critical Care Network for Northern Ireland reports on critical care patients with confirmed influenza;
- Mortality data from Northern Ireland Statistics and Research Agency (NISRA);
- Excess mortality estimations are also provided by Public Health England using the EuroMOMO (Mortality Monitoring in Europe) model based on raw death data supplied by NISRA

NB: Please note changes in the y axes on figures 1 – 6 from last season's bulletin when interpreting the charts contained in this season's bulletin.

## **Sentinel GP Consultation Data**

Figure 1. Sentinel GP consultation rates for flu/FLI 2014/15 - 2016/17




Figure 2. Sentinel GP combined consultation rates for flu/FLI and number of influenza positive detections 2011/12 – 2016/17





Figure 3. Sentinel GP consultation rates for flu/FLI and number of virology 'flu detections from week 40, 2015



## Comment

GP consultation rates have decreased in week 12, 2017 to 11.2 per 100,000 population from 12.8 per 100,000 population in week 11. The GP consultation rate in week 12 is lower than the same period in both 2015/16 (33.7 per 100,000 population) and 2014/15 (23.5 per 100,000 population).

Rates remain below the pre-epidemic Northern Ireland 2016/17 threshold of 47.9 per 100,000 (Figures 1, 2 and 3).




Figure 4. Sentinel GP age-specific consultation rates for flu/FLI from week 40, 2015

#### Comment

Sentinel GP flu/FLI consultations have increased among the 5-14 and 45-64 years age groups in week 12, with a decrease noted among all other age groups.

In week 12, 2017 the highest age-specific rate was noted among those aged 65 years and over (16.5 per 100,000 population), with the lowest rate represented by those aged 0-4 years (zero consultations).

Age-specific consultation rates are lower among almost all age groups in week 12 than the same time period in both 2015/16 and 2014/15 (Figure 4).

# **Out-of-Hours (OOH) Centres Call Data**

Figure 5. OOH call rate for flu/FLI, 2014/15 – 2016/17





Figure 6. OOH Call rates of flu/FLI by age-group from week 40, 2015



#### Comment

During week 12, 2017 the OOH GP consultation rate increased to 2.6 per 100,000 population from 4.1 per 100,000 population in week 11. The OOH GP consultation rate in week 12 is lower

than the same period in both 2015/16 (9.6 per 100,000 population) and 2014/15 (7.4 per 100,000 population) (Figure 5).

The proportion of calls related to flu has remained stable and still represents less than 1% of total calls to the OOH service in week 12, 2017.

During week 12, OOH flu/FLI rates have decreased among the 0-4, 15-44 and 45-64 years age groups while rates among those aged 5-14 years and 65 years and over remained relatively stable. The highest age-specific OOH flu/FLI rate in week 12 was again noted among the 15-44 years age group (3.3 per 100,000 population) while those aged 0-4 years represented the lowest rate (0.8 per 100,000 population) (Figure 6).

Age-specific rates in week 12 are lower among all age groups than those noted during the same period in both 2015/16 and 2014/15.

# **Virology Data**

Table 1. Virus activity in Northern Ireland by source, Week 12, 2016/17									
Source	Specimens Tested	Flu AH3	Flu A(H1N1) 2009	A (untyped)	Flu B	RSV	Total influenza Positive	% Influenza Positive	
Sentinel	2	0	0	0	0	0	0	0%	
Non-sentinel	191	1	0	2	4	0	7	4%	
Total	193	1	0	2	4	0	7	4%	


Table 2. Cumulative virus activity from all sources by age group, Week 40 - 12, 2016/17									
	Flu AH3	Flu A(H1N1) 2009	A (untyped)	Flu B	Total Influenza	RSV			
0-4	18	0	6	2	26	450			
5-14	12	0	3	1	16	16			
15-64	233	1	54	20	308	98			
65+	275	1	70	15	361	138			
Unknown	0	0	0	0	0	0			
All ages	538	2	133	38	711	702			

Table 3. Cumulative virus activity by age group and source, Week 40 - Week 12, 2016/17												
	Sentinel						Non-sentinel					
	Flu AH3	Flu A(H1N1) 2009	A (untyped)	Flu B	Total Influenza	RSV	Flu AH3	Flu A(H1N1) 2009	A (untyped)	Flu B	Total Influenza	RSV
0-4	0	0	0	0	0	1	18	0	6	2	26	449
5-14	4	0	0	0	4	0	8	0	3	1	12	16
15-64	29	1	5	3	38	8	204	0	49	17	270	90
65+	5	1	1	1	8	3	270	0	69	14	353	135
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
All ages	38	2	6	4	50	12	500	0	127	34	661	690

#### Note

All virology data are provisional. The virology figures for previous weeks included in this or future bulletins are updated with data from laboratory returns received after the production of the last bulletin. The current bulletin reflects the most up-to-date information available. Sentinel and non-sentinel samples are tested for influenza and for RSV. Cumulative reports of influenza A (untyped) may vary from week to week as these may be subsequently typed in later reports.

Figure 7. Number of samples tested for influenza and proportion positive, 2015/16 and 2016/17, all sources



#### Comment

During week 12, 2017 there were 193 specimens submitted for virological testing. There were 7 detections of influenza in total (positivity rate of 4%) (Figure 7). There was 4 detections of influenza B, 1 detection of influenza A(H3) and 2 detections of influenza A (typing awaited). There were no detections of influenza A(H1N1)pdm09.

There were no samples positive for influenza submitted through the GP based sentinel scheme across Northern Ireland.

This season to date there have been a total of 711 detections of influenza, of which 538 have been typed as influenza A(H3). There have been 38 detections of influenza B, 133 of influenza A (typing awaited), and 2 detections of influenza A(H1N1)pdm09 (Tables 1, 2, and 3).

# **Respiratory Syncytial Virus**

450 50% 45% 400 40% 350 35% 300 30% 250 Number of tests 25% 200 20% 150 15% 100 10% 50 5% 0% 40 46 48 50 52 2 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Week 2015/16 No tested 2016/17 No tested 2015/16 proportion positive 2016/17 proportion positive


Figure 8. Number of samples tested for RSV and proportion positive, 2015/16 and 2016/17, all sources

#### **Comment**

During week 12, 2017 there were no positive detections of RSV, giving a lower positivity rate than the same period in 2015/16 (1%). To date there have been a total of 702 detections of RSV of which the majority (64%) were in those aged 0-4 years (Figure 8 and Table 2).

### **ICU/HDU Surveillance**

Figure 9. Confirmed ICU influenza cases by week of specimen, with sentinel ILI consultation rate, 2014/15 - 2016/17



#### Comment

Data are collected on laboratory confirmed influenza patients and deaths in critical care (level 2 and level 3).

During week 12, one confirmed case of influenza in ICU was reported to the PHA. There were no deaths reported in ICU patients with laboratory confirmed influenza.

There have been 40 confirmed cases of influenza in ICU reported this season to date, of which 31 have been typed as influenza A (H3), eight as influenza A (typing awaited) and one influenza B. There have been seven deaths reported in confirmed cases of influenza in ICU this season to date.

## **Outbreak Surveillance**

During week 12, 2017 there were no confirmed influenza outbreaks reported to the PHA. There have been a total of 11 confirmed influenza outbreaks reported this season to date, of which eight have been confirmed as influenza A(H3) and three as influenza A (typing awaited).

# **Mortality Data**

Weekly mortality data is provided from Northern Ireland Statistics and Research Agency. The data relates to the number of deaths from selected respiratory infections (some of which may be attributable to influenza, and other respiratory infections or complications thereof) registered each week in Northern Ireland. This is not necessarily the same as the number of deaths occurring in that period. Searches of the medical certificates of the cause of death are performed using a number of keywords that could be associated with influenza (bronchiolitis, bronchitis, influenza and pneumonia). Death registrations containing these keywords are presented as a proportion of all registered deaths.

Figure 10. Weekly registered deaths

#### Comment

Week

During week 12, 2017 the proportion of deaths related to respiratory keywords has increased to 31% from 30% in week 11. In week 12 there were 356 registered deaths, of which 109 related to specific respiratory infections (Figure 10).

The proportion of deaths attributed to specific respiratory infections is lower at this point in the season than during the same period in 2015/16 (35%) and 2014/15 (37%).

## **EuroMOMO**

EuroMOMO data will be available later in the season.

## **Influenza Vaccine Uptake**

To 31<sup>st</sup> January 2017, provisional data suggested that vaccine uptake for those aged 65 years and over was 71.7%, higher than the same period in the 2015/16 (66.5%); while 55.9% of those under 65 and in an at risk group had received the vaccine, higher than in 2015/16 when 53.2% had received the vaccine in this group during the same period.

Similar to last season, all children aged between 2 and 4 years and all primary school children in 2016/17 have been offered the seasonal influenza vaccine. To 31<sup>st</sup> January 2017, provisional data suggested that vaccine uptake among 2-4 year old children was 52.0%, higher than in 2015/16 when 45.9% had received the vaccine during the same period. Provisional data suggests uptake among children in primary school was 78.2%, also higher than in 2015/16 when 76.5% had received the vaccine during the same period.

# **International Summary**

### Europe

#### Week 11, 2017

- Influenza activity across the region continued to decrease with the great majority of countries reporting low intensity.
- The proportion of influenza virus detections among sentinel surveillance specimens continued to decrease, to 17% from 22% in the previous week.
- This was the first week during the season that the proportion of type B viruses exceeded
  the proportion of type A viruses in sentinel detections, as is commonly seen in the second
  half of an influenza season. However, the overall number of type B detections remained
  low.

### Season Overview:

- Influenza activity started early this season, in week 46/2016, which is the earliest week
  that the overall influenza virus-positivity rate in sentinel specimens reached 10% since the
  emergence of A(H1N1)pdm09 viruses in 2009/10.
- Since week 40/2016, influenza A viruses have predominated, accounting for 94% of all sentinel detections; the great majority (99%) of subtyped influenza A viruses from sentinel sites being A(H3N2).
- Confirmed cases of influenza virus type A infection reported from hospitals have predominantly been in adults aged 65 years or older. Excess all-cause mortality has been observed substantially in people aged 15–64 years and markedly in people aged 65 years or older in the majority of the 19 reporting countries. This is commonly seen when the predominant viruses circulating are A(H3N2).
- Two-thirds of the A(H3N2) viruses genetically characterized belong to genetic subclade (3C.2a1), which are in the main antigenically similar to the clade 3C.2a vaccine virus, as mentioned in the WHO recommendations for vaccine composition for the northern hemisphere 2017–18.

- Recent vaccine effectiveness estimates for all age groups against A(H3N2) illness from Canada (42%), the US (43%) and Europe (38%) are consistent for persons aged 65 years or older.
- Given typically suboptimal vaccination coverage and the partial effectiveness of influenza vaccines, rapid use of neuraminidase inhibitors (NAIs) for laboratory-confirmed or probable cases of influenza virus-infection should be considered for vaccinated and nonvaccinated patients at risk of developing complications.
- Of the viruses tested so far, only one A(H3N2) virus (<1%) has shown reduced susceptibility to oseltamivir this season.
- The progression of the season has confirmed the conclusions of the ECDC risk
  assessment on seasonal influenza updated on 25 January 2017, namely that expected
  severe outcomes in the elderly related to the prevalence of A(H3N2) viruses, putting some
  health care systems under pressure.

## http://www.flunewseurope.org/

# Worldwide (WHO) and CDC

## As at 20th March 2017:

Influenza activity in the temperate zone of the northern hemisphere appeared to decrease. Influenza activity in many countries especially in East Asia and Europe already peaked. Worldwide, influenza A(H3N2) virus was predominant. In South Asia influenza activity with mainly H1N1 has been increasing. The majority of influenza viruses characterized so far were similar antigenically to the reference viruses contained in vaccines for use in the 2016-2017 northern hemisphere influenza season. Nearly all tested viruses collected recently for antiviral sensitivity were susceptible to the neuraminidase inhibitor antiviral medications.

- In North America, overall influenza and other respiratory virus activity decreased in Canada and United States of America. Influenza activity slightly increased in Mexico with influenza A(H1N1)pdm09 virus predominating.
- In Europe, influenza activity appeared to decrease with influenza A (H3N2) and influenza B viruses predominant in the region. Detections of influenza B virus increased in the recent weeks. Persons aged over 65 years continued to be reported as most frequently associated with severe disease from influenza infection.
- In East Asia, influenza activity continued to decrease with influenza A(H3N2) virus predominant.
- In Western Asia, influenza activity continued to decrease with influenza A(H3N2) and B viruses co-circulating in the region.
- In Southern Asia, influenza activity continued to increase in India, the Maldives and Sri Lanka, with mainly influenza A(H1N1)pdm09 virus reported followed by influenza B virus.
- In South East Asia, influenza activity remained low.
- In Northern Africa, low influenza activity was reported in Tunisia, with influenza A(H3N2) and influenza B virus co-circulating.
- In West Africa, influenza activity continued to be reported in Ghana and Mali, with influenza B being the main virus detected. In Eastern Africa, influenza activity was reported in Ethiopia and Mauritius with influenza A(H3N2) virus predominant.
- In the Caribbean countries and Central America, influenza and other respiratory virus activity remained low in general.
- In tropical South America, influenza and other respiratory virus activity remained low, although RSV activity remained elevated in Colombia.
- In the temperate zone of the Southern Hemisphere, influenza activity was at interseasonal levels. National Influenza Centres (NICs) and other national influenza

laboratories from 94 countries, areas or territories reported data to FluNet for the time period from 20 February 2017 to 05 March 2017 (data as of 2017-03-17 09:50:51 UTC). The WHO GISRS laboratories tested more than 156226 specimens during that time period. 34376 were positive for influenza viruses, of which 26581 (77.3%) were typed as influenza A and 7795 (22.7%) as influenza B. Of the sub-typed influenza A viruses, 651 (8.1%) were influenza A(H1N1)pdm09 and 7392 (91.9%) were influenza A(H3N2). Of the characterized B viruses, 614 (71.4%) belonged to the B-Yamagata lineage and 246 (28.6%) to the B-Victoria lineage.

 The vaccine recommendation for the 2017-2018 northern hemisphere influenza season was made and can be consulted at this link below: <a href="http://www.who.int/influenza/vaccines/virus/recommendations/2017\_18\_north/en/">http://www.who.int/influenza/vaccines/virus/recommendations/2017\_18\_north/en/</a>

http://www.who.int/influenza/surveillance\_monitoring/updates/latest\_update\_GIP\_surveillance/en\_/index.html

http://www.cdc.gov/flu/weekly/

## **Acknowledgments**

We would like to extend our thanks to all those who assist us in the surveillance of influenza in particular the sentinel GPs, Out-of-Hours Centres, Apollo Medical, Regional Virus Laboratory, Critical Care Network for Northern Ireland, Public Health England and NISRA. Their work is greatly appreciated and their support vital in the production of this bulletin.

## **Further information**

Further information on influenza is available at the following websites:

http://www.fluawareni.info

https://www.gov.uk/government/organisations/public-health-england

http://www.publichealth.hscni.net

http://www.who.int

http://ecdc.europa.eu

http://euroflu.org

Internet-based surveillance of influenza in the general population is undertaken through the FluSurvey. A project run jointly by PHE and the London School of Hygiene and Tropical Medicine. If you would like to become a participant of the FluSurvey project please do so by visiting the <u>Flusurvey website</u> for more information.

## Detailed influenza weekly reports can be found at the following websites:

Republic of Ireland:

http://www.hpsc.ie/hpsc/A-

Z/Respiratory/Influenza/SeasonalInfluenza/Surveillance/InfluenzaSurveillanceReports/

### England:

https://www.gov.uk/government/statistics/weekly-national-flu-reports

#### Scotland

http://www.hps.scot.nhs.uk/resp/seasonalInfluenza.aspx

#### Wales

http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=34338

For further information on the Enhanced Surveillance of Influenza in Northern Ireland scheme or to be added to the circulation list for this bulletin please contact:

Chris Nugent Surveillance Officer Public Health Agency 028 9536 3407 Dr Naomh Gallagher Senior Epidemiological Scientist Public Health Agency 028 9536 3498

Email: flusurveillance@hscni.net

This report was compiled by Chris Nugent, Cathriona Kearns, Dr Naomh Gallagher and Dr Muhammad Sartaj.